Calvin Sandra 4
4 · Travere Therapeutics, Inc. · Filed Dec 16, 2025
Insider Transaction Report
Form 4
Calvin Sandra
SVP, CHIEF ACCOUNTING OFFICER
Transactions
- Sale
Common Stock
2025-12-15$36.00/sh−2,910$104,760→ 45,635 total
Footnotes (1)
- [F1]This sale was made pursuant to a written plan adopted on June 10, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.